Extended Data Table 2 Adverse events with an incidence of 5% or more of participants in either randomized group

From: Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial

  1. Events are reported from most to least frequent. No serious adverse events were reported during the study period. Experiencing an AE was not associated with likelihood of achieving a ≥5% loss from randomization in phentermine-treated participants. aOne of these individuals was later lost to follow-up, the remainder completed at least some portions of the week-24 assessment. Reasons for discontinuation were: four participants (two placebo and two phentermine) elected to pause or discontinue following an adverse event unlikely or definitely unrelated to their participation; three (one placebo and two phentermine) stopped attending all treatments due to perceived lack of efficacy; one phentermine-treated participant ran out of medication before the final assessment due to a missed refill visit. No participants were terminated or downtitrated at the recommendation of the study team. BT, behavioral treatment; AOM, anti-obesity medication; COVID-19, coronavirus disease of 2019.
Back to article page